stockrowApnimed, Inc.
APMDApnimed, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $38.5 million, up 380.1% from fiscal 2024.
Follow APMD
Alert me
Apnimed, Inc. (APMD) Return on invested capital
Apnimed, Inc.'s return on invested capital over the twelve months to 30 June 2026 was 0.00%, down 0.0 percentage points from fiscal 2025 (0.00%). That is in line with the Biotechnology industry median of 0.00% and in line with the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | 0.00% | 0.00 |
| FY2024 | 0.00% | — |
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| NVCT Nuvectis Pharma, Inc. compare | 0.00% |
| IMMX Immix Biopharma, Inc. compare | 0.00% |
| OBX Obsidian Therapeutics, Inc compare | 0.00% |
| APMD Apnimed, Inc. | 0.00% |
| KURA Kura Oncology, Inc. compare | 0.00% |
| AVBP ArriVent BioPharma, Inc. compare | 0.00% |
| DSGN Design Therapeutics, Inc. compare | 0.00% |
| OLMA Olema Pharmaceuticals, Inc. compare | 0.00% |
| GERN Geron Corporation compare | −34.1% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)